Resources & Guides
Educational content about GLP-1 medications, pharmacokinetics, and optimizing your treatment journey.
GLP-1 Medication Hubs
Comprehensive guides for each GLP-1 medication—dosing protocols, clinical trial data, microdosing strategies, and our free calculators.
Semaglutide Guide
Ozempic & Wegovy: GLP-1 receptor agonist. ~15% weight loss, 7-day half-life. FDA-approved for diabetes and weight management.
Tirzepatide Guide
Mounjaro & Zepbound: Dual GLP-1/GIP agonist. ~21% weight loss, 5-day half-life. The first dual-agonist approved by FDA.
Retatrutide Guide
Triple GLP-1/GIP/Glucagon agonist. ~24% weight loss in trials, 6-day half-life. Expected FDA approval 2027.
Educational Content
Retatrutide Muscle Mass Preservation: What the DEXA Data Shows
articleRetatrutide does not prevent lean mass loss, but the proportion lost is similar to other obesity treatments. Here is what the DEXA data shows, why the glucagon receptor is only a hypothesis, and what actually protects muscle.
Retatrutide TRIUMPH-1 Cardiometabolic Outcomes Explained
articleThe TRIUMPH-1 secondary dataset presented at ADA 2026 goes beyond weight loss. Triglycerides fell 41.0%, non-HDL cholesterol 24.2%, systolic blood pressure 12.3 mmHg, and nested substudies showed up to 73.1% less knee pain and up to 60.6% less sleep apnea on retatrutide 12mg.